Clinical Trials Logo

Pancreatic Cancer Metastatic clinical trials

View clinical trials related to Pancreatic Cancer Metastatic.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06155136 Active, not recruiting - Clinical trials for Pancreatic Cancer Metastatic

RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan

NALLONG
Start date: October 6, 2023
Phase:
Study type: Observational

The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI

NCT ID: NCT04469556 Active, not recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma Signature Stratification for Treatment

PASS-01
Start date: October 14, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, and drug testing sensitivity and other biomarkers.

NCT ID: NCT03984214 Active, not recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Start date: December 16, 2019
Phase: Phase 3
Study type: Interventional

Aim of this phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.